Delivery Order SPE2DB20D1050-SPE2DB25FH91M
- Not listed
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of UBRELVY 50 mg tablets (10-count unit dose packaging) with a ceiling value of $4,919.80 and an ultimate completion date of August 4, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The contract represents a child order under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,381.64 for UBRELVY 50 MG tablets (10-unit dose packaging) on September 8, 2025, with completion scheduled for September 9, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999,999,999.00 through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of UBRELVY 50 mg tablets in unit-dose packaging (10 units per package). This competitive award, valued at $30,906.84, represents a firm fixed-price delivery order with an ultimate completion date of July 25, 2025. The contract carries no set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of UBRELVY 100 MG tablets in unit dose packaging (10 tablets per unit). This competitively awarded, firm fixed-price delivery order has a ceiling value of $6,583.77 and an ultimate completion date of September 17, 2025. The contract is issued without a set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order valued at $6,244.42 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablet unit dose packages (16 count) on September 8, 2025, with completion expected by September 9, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of the company's pharmaceutical supply support to federal military and healthcare systems. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of UBRELVY 100 mg tablets in unit dose packages of 10, with a ceiling value of $7,203.43. This is a firm fixed price delivery order with an ultimate completion date of July 24, 2025, and represents a child contract under AmerisourceBergen's larger pharmaceutical supply agreements. The contract was competitively awarded with no set-aside designation, and performance...
- The Defense Logistics Agency awarded a $7,463.51 delivery order to AmerisourceBergen Drug Corp on June 6, 2025, for the supply of UBRELVY 100 MG tablets (unit dose, 10-count packages). This firm fixed price delivery order, which is not set-aside designated, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of UBRELVY 100 mg tablets (Unit Dose, 10 count packages) with a ceiling value of $3,362.34. This is a firm fixed-price delivery order with an ultimate completion date of August 25, 2025, and represents a non-set-aside, competitively awarded contract. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for UBRELVY 50 MG tablets (10-count unit dose packaging) valued at $1,719.90 under a firm fixed-price delivery order contract type. The award was issued on August 27, 2025, with an ultimate completion date of August 28, 2025, with no set-aside designation applied. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is the prime contractor on this delivery order, which represents...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of UBRELVY 50 mg tablets in unit dose packaging (10 count). This order, valued at $5,439.62 with a firm fixed price structure, represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, with a...
- SPE2DB20D1050Indefinite Delivery Contract
- SPE2DB20D1050-SPE2DB25FH91MDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of UBRELVY 50 mg tablets in unit-dose packaging of 10s. This competitively awarded contract, valued at $9,038.71, carries a firm fixed price and is scheduled for completion by September 17, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999,999,999.00 ceiling value through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical federal vendor supplying pharmaceutical products and medical supplies to military and veteran healthcare systems. As the prime contractor on this IDC, the company fulfills orders for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems across multiple therapeutic domains. UBRELVY, a migraine treatment medication, is among the specialty pharmaceuticals distributed through this comprehensive contract vehicle. The contract was not designated with a set-aside provision, confirming AmerisourceBergen's selection through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.0k | 9/16/25 |